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Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute
pelvic infections.
Methods: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of
two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then
randomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administered
intravenously.
Results: In total, 163 patientsin the ertapenem groupand 153 patientsin the piperacillin–tazobactam groupwere
clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common
single pathogen was Escherichia coli. At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients
who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95%
confidence interval for the difference, adjusting for strata, -4% to 8.8%), indicating that cure rates for both
treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by
stratum and severity of infection. The frequency and severity of drug-related adverse events were generally
similar in both groups.
Conclusions: Inthisstudy,ertapenemwasaseffectiveaspiperacillin–tazobactamforthetreatmentof acutepelvic
infection,wasgenerallywelltolerated,andhadanoverallsafetyprofilesimilartothatofpiperacillin–tazobactam.
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These data were presented in part at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL,
December 2001.Acute soft tissue pelvic infections in women
include several diagnoses that may be categorized
as infections related to delivery and those which
occur after gynecological surgery. Risk factors
for acute pelvic infection are delivery by
Cesarean section, hysterectomy or septic incom-
plete abortion. Although these procedures are
often preceded or followed (for Cesarean section)
by antimicrobial prophylaxis, the rate of infection
may be as high as 20%1. Acute pelvic infections
are usually polymicrobial. The major causal
pathogens are those that comprise the normal
vaginal flora, namely Streptococcus agalactiae,
Escherichia coli, peptostreptococci, Prevotella spp.,
Bacteroides spp. and Gardnerella vaginalis. Anti-
microbial regimens for the treatment of acute
pelvic infection must therefore provide coverage
against a broad spectrum of aerobic and anaerobic
bacteria. Examples of effective regimens include
combination therapy with an aminoglycoside and
an agent such as metronidazole or clindamycin
that provides anaerobic coverage, ormonotherapy
with agents that are dosed multiple times a day,
such as cefoxitin, an extended-spectrum peni-
cillin, or a b-lactam/b-lactamase inhibitor like
piperacillin–tazobactam.
Ertapenem (Merck & Co., Inc., formerly
MK-0826, Whitehouse Station, NJ) is a once-a-
day parenteral b-lactam agent that can be used
as monotherapy for the treatment of several
community-acquired and mixed aerobic and
anaerobic infections, including acute pelvic infec-
tions, complicated intra-abdominal, skin and
urinary tract infections, and community-acquired
pneumonia.Thisfocused-spectrumcarbapenem is
highly active in vitro against many Gram-positive
and Gram-negative aerobes and anaerobes that in
general are associated with community-acquired
infections, but has minimal activity against Pseudo-
monas aeruginosa, Acinetobacter spp. and entero-
cocci2,3. The bacteria that are usually susceptible
to ertapenem include S. agalactiae and many
Enterobacteriaceae, other aerobic streptococci,
and Gram-positive and Gram-negative anaerobes,
which are the pathogens most commonly
responsible for acute pelvic infections.
The objective of this study was to compare the
efficacy, tolerability and safety of ertapenem 1 g
once a day with those of piperacillin–tazobactam
3.375 g every 6 hours for the treatment of women
with moderate to severe acute pelvic infection.
SUBJECTS AND METHODS
Patients
Females aged ‡ 16 years diagnosed with acute
pelvic infection were eligible for inclusion in the
study if they required at least 3 days of parenteral
antimicrobial therapy and if the infection was
caused by a pathogen susceptible to the study
drugs. Criteria for acute pelvic infection included
an oral temperature of > 38°C (or equivalent),
white blood cell (WBC) count > 10 500/ml or
> 10% immature granulocytes, and at least one
of the following: pelvic, abdominal or uterine
pain, cramping or tenderness, or an imaging study
suggesting pelvic abscess or infection. Vaginal
delivery, Cesarean section or gynecological
surgery must have been performed between
24 hours and 1 month before enrollment. Patients
with septic abortion could represent no more
than 15% of the total enrollment.
Patients with any of the following were
excluded from the study: pregnancy or lactation,
history of serious allergy, hypersensitivity, or
intolerance of study therapy (patients with a
history of mild rash in response to b-lactams could
be enrolled), pelvic inflammatory disease, tubo-
ovarian abscess, postoperative abdominal wall
infection, gynecological malignancy, any rapidly
progressive disease, immunocompromising illness
or therapy, AIDS (patients with HIV infection
could be enrolled if they met the inclusion
criteria), the need for concomitant antimicrobials
(other than vancomycin, which was permitted for
treatment of resistant Gram-positive pathogens in
a mixed infection, or antifungal agents), acute
hepatic failure, the need for peritoneal dialysis or
hemodialysis, hypotension, a baseline pathogen
resistant to either study drug, treatment with a
systemic antimicrobial agentfor‡ 24 hourswithin
72 hours prior to admission to the study (unless
failure of the prior regimen was documented),
aspartate or alanine aminotransferase > 6 times
theupperlimit ofnormal(ULN), bilirubinoralka-
line phosphatase > 3 times ULN, absolute neutro-
phil count £ 1000/ml, platelet concentration
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< 6 g/dl, or coagulation tests > 1.5 ULN.
Study design and antimicrobial therapy
This prospective, double-blind (with sponsor
blinding), randomized study was conducted from
November 1998to May2000, at 47sites, ofwhich
30 sites (63.8%) were in the USA. In total, 17 sites
enrolled 76.0% of the patients (‡ 10 patients/site).
Written informed consent was obtained from all
patients, and the institutional review board at
each participating site approved the protocol and
consent form. Eligible patients were stratified as
follows. Stratum I consisted of patients with
obstetric or postpartum infection (including septic
abortion), and patients with gynecological or
postoperative infection were included in Stratum
II. Randomization in a 1 : 1 ratio (ertapenem:
piperacillin–tazobactam) was performed using an
allocation schedule that employed computer-
generated random numbers.
Ertapenem 1 g once a day and piperacillin–
tazobactam 3.375 g every 6 hours were given
as intravenous (IV) infusions over a period of
30 minutes. The duration of treatment was deter-
mined by the investigator, and was usually
3–10 days. For patients with a creatinine clearance
of < 30 ml/min/1.73 m2, the dose of ertapenem
was 500 mg once a day. The dose of piperacillin–
tazobactam was adjusted to 2.25 g every 6 hours
if the creatinine clearance was in the range
20–40 ml/min/1.73 m2, and to 2.25 g every
8 hours if the creatinine clearance was
< 20 ml/min/1.73 m2. To ensure blinding,
patients in the ertapenem group also received
subsequentmatching placebo infusionsof 50 ml of
normal saline every 6 hours. After at least 2 days
of hospital infusion therapy, study therapy could
becompletedinthehospital,ataclinicorathome.
Clinical assessments
Patients were evaluated at enrollment and daily
thereafter while on parenteral study therapy. The
clinical response was measured at the completion
ofparenteraltherapyand 2–4 weeks posttherapy–
the test of cure (TOC) visit. The severity of the
patient’s infection was assessed prior to unblinding
on the basis of prespecified criteria (patients who
were hemodynamically unstable were not eligible
for enrollment in the study). The infection
was considered to be severe if the patient was
bacteremic at baseline or had fever > 39°C. All
otherinfectionswereconsideredtobeofmoderate
severity. The clinical responses at the TOC visit
were categorized as cure, presumptive cure (reso-
lution of signs and symptoms of pelvic infection
confirmed by telephone contact), failure (defined
as death from acute pelvic infection, incomplete
resolutionorworseningofsymptomsthatrequired
additional antimicrobial therapy, surgical inter-
vention for pelvic infection > 24 hours after entry
to the study, or surgical site infection that required
additional antimicrobial therapy) or indeterminate
(datanotavailable forevaluation ofefficacy).Tobe
considered an evaluable failure, patients had to
have received at least 48 hours of study anti-
microbial therapy.
Microbiological assessments
At enrollment, a specimen for aerobic and anaero-
bic culture was collected at surgery fromthesite of
pelvic infection or, for patients with endometritis,
from the endometrium by using a protected
sampling device; high vaginal swabs were not
acceptable. Subsequent pelvic cultures were only
obtained if signs of ongoing or new pelvic infec-
tion were present. Blood cultures were performed
if the patient had chills and/or a temperature of
‡ 39°C. All isolates were identified at the site
laboratory, and aerobic pathogens were tested
for in-vitro susceptibility to ertapenem and
piperacillin–tazobactam following the guidelines
oftheNationalCommittee forClinicalLaboratory
Standards4.Inaddition,studysitesoutsidetheUSA
sent a duplicate clinical sample in an anaerobic
transport tube (Anaerobe Systems, Morgan Hill,
CA)toacentrallaboratory(R.M.AldenResearch
Laboratory, Santa Monica, CA) for culture and
susceptibility testing of anaerobes.
The microbiological outcomes were catego-
rized as eradication, presumptive eradication (no
material available for culture in patients who were
clinically cured; repeat cultures were required
only in the context of clinical failure), persist-
ence, persistence acquiring resistance, presumed
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sidered to be clinical failures) or indeterminate
(microbiological response could not be deter-
mined for any reason). Gram-positive pathogens
treated with vancomycin were considered to have
indeterminate microbiological outcomes. Treat-
ment with vancomycin did not affect clinical
assessability. Favorable microbiological outcomes
were eradication and presumptive eradication.
Populations for analysis
The treated population included all randomized
patients who received at least one dose of study
therapy. The clinical modified intent-to-treat
(MITT) population consisted of treated patients
who met the minimum disease definition. The
clinically evaluable (per protocol)populationwas a
subset of the clinical MITT population for whom
information was sufficient to determine outcome
at the TOC visit, and if baseline pathogens were
present,at leastoneofthesewassusceptibletoboth
study antimicrobials. Microbiologically evaluable
patients were those clinically evaluable patients
who had a baseline pathogen identified and a
microbiological response assessed.
Efficacy variables
The primary efficacy variable in this study was
the clinical response assessment in the clinically
evaluable population at the TOC visit. Additional
efficacyassessments were theclinicalresponse rates
in the supportive clinical MITT population at the
TOC visit and in the clinically evaluable popula-
tion at completion of IV therapy, and the propor-
tion of microbiologically evaluable patients with
a favorable microbiological response at the
TOC visit.
Safety and tolerability assessment
All patients who received at least one dose of
the study therapy were evaluated for safety and
tolerability. Patients were monitored daily for
adverse experiences during parenteral therapy
and for 14 days thereafter. The intensity (mild,
moderate or severe) of the adverse event and the
likelihood of its being related to the study drug
(definitely not, probably not, possibly, probably
or definitely) were assessed by the investigator.
The tolerability of each study drug at the local
infusion site was evaluated daily by the
investigator.
Statistical analyses
The study was designed to test for equivalence
in efficacy of the ertapenem and piperacillin–
tazobactam clinically evaluable treatment groups.
The sample size (a minimum of 150 evalu-
able patients per group) was calculated using
Blackwelder’s formula5 and for the following
values: alpha, 0.025; beta, 0.20; expected response
rate in the comparator arm, 90%. Equivalence for
this study was determined by calculation of the
95% (two-sided) confidence interval (CI) for
the difference in response rates between the two
treatment groups (ertapenem minus piperacillin–
tazobactam). If the observed response rate in the
comparator group was > 90%, for equivalence to
be demonstrated, the CI of the difference had
to contain zero and its lower limit could not be
less than -10%. CIs about the difference were
calculated using the normal approximation to the
binomial distribution, and were adjusted for strata
using the Cochran–Mantel–Haenzel approach6.
The treatment ´ stratum interaction was investi-
gated using the Breslow–Day test of homogeneity
of odds ratios and the Gail–Simon test, if needed.
An exploratory analysis using Kaplan–Meier
curves was also performed to examine time
to defervescence during therapy in clinically
evaluablepatientswhowerecured.Noformaltests
were performed based on baseline demographics
or disease characteristics (e.g. severity).
RESULTS
Patients
The distribution of the study patients is summa-
rized in Figure 1. In total, 38 patients signed a
consent form but were notrandomized. The most
common reasons why patients were not random-
ized were failure to meet the criteria for diagnosis
of acute pelvic infection (18 patients), withdrawal
of consent (5 patients), and presence of a con-
current infection that would have interfered with
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therapy (four patients). In total, 412 patients were
randomized, 216 patients in the ertapenem group
and 196 patients in the piperacillin– tazobactam
group, of whom 163 subjects (75.5%) and 153
subjects (78.1%), respectively, were clinically
evaluable. Themostcommonreasonswhypatients
were not clinically evaluable were assessments
outside the protocol-defined follow-up period,
and inadequate or inappropriate courses of study
therapy.
The baseline demographics of the patients who
signed a consent form but were not randomized
appearedtobecomparabletothoseoftherandom-
ized population (data not shown). The baseline
demographics and disease characteristics of the
two treatment groupsin therandomized and clini-
cally evaluable populations were generally similar
(Table 1). The majority of patients in both
populations were in stratum I (obstetric/
postpartum infection), and the most common
diagnosis at entry was endomyometritis (present
in approximately 75% of patients in both
populations). In approximately 25% of patients
the infection was rated as severe.
Therapy
The dosage of study drug was adjusted for renal
insufficiencyinfourpatients(oneintheertapenem
group and three in the piperacillin–tazobactam
group), all of whom were considered not to be
clinically evaluable for reasons other than elevated
creatinine clearance values. The duration of
studytherapyinthetreated and clinicallyevaluable
patients was comparable in the ertapenem
and piperacillin–tazobactam treatment groups
(Table 1). The median duration was 4 days in each
treatment group of both populations. Six patients
received vancomycin for resistant Gram-positive
pathogens; none of them met the criteria for
inclusion in the clinically evaluable population.
Baseline microbiology
Of the clinically evaluable patients, 128 patients
(78.5%) in the ertapenem group and 129 patients
(84.3%) in the piperacillin–tazobactam group had
at least one pathogen isolated at baseline. In total,
93 microbiologically evaluable patients (72.7%)
who received ertapenem and 93 patients (72.1%)
who received piperacillin–tazobactam had poly-
microbic infections. The distribution of the
pathogens in each treatment group of the micro-
biologically evaluable population and their
susceptibility profileswerecomparable.Anaerobes
accounted for 60.8% (257/423) of the isolates in
the ertapenem group and 58.6% (238/406) of the
isolates in the piperacillin–tazobactam group. The
most common single isolate in each group was
E. coli (41 (9.7%) and 39 (9.6%) in the ertapenem
and piperacillin–tazobactam groups, respectively).
Most isolates were susceptible to bothstudy drugs,
with the exception of enterococci, which were
often intermediate or resistant to ertapenem. In
total, ten microbiologically evaluable patients in
the ertapenem group (five with endometritis and
five with septic abortion) and six patients in the
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Randomized to therapy = 412
Treated with ertapenem = 216
Clinical MITT population = 211
Microbiological MITT population = 161
Clinical evaluable population = 163 Clinical evaluable population = 158
Microbiologically evaluable population = 128
Microbiological MITT population = 158
Microbiologically evaluable population = 129
Treated with piperacillin–tazobactam = 196
Clinical MITT population = 191
Figure 1 Profile of patient enrollment. MITT, modified intent to treatpiperacillin–tazobactam group (two with endo-
metritis, two with septic abortion and two with
pelvic cellulitis) were bacteremic at baseline. In
patients who received ertapenem, causal patho-
gens were E. coli (n = 6) and one each of
the following: Listeria monocytogenes, Enterobacter
cloacae, Klebsiella pneumoniae and Prevotella loescheii.
In those who received piperacillin–tazobactam,
causal pathogens were E. coli (n = 2) and one each
of the following: E. cloacae, Streptococcus pyogenes,
Peptostreptococcus asaccharolyticus, Streptococcus spp.,
Arcanobacterium bernardiae and Corynebacterium
spp. (the latter two organisms were recovered
from one patient).
Efficacy
At the primary efficacy endpoint, 93.9% of the
clinically evaluable patients in the ertapenem
group and 91.5% of those in the piperacillin–
tazobactam group were cured (95% CI for the
difference, adjusting for strata, -4.0% to 8.8%),
indicating equivalence between the two treat-
ments.ClinicalsuccessratesattheTOCassessment
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Randomizeda Clinically evaluable
Characteristic
Ertapenem
(n = 216)
Pip–Taz
(n = 196)
Ertapenem
(n = 163)
Pip–Taz
(n = 153)
Ethnicity (percent)
Caucasian
Black
Hispanic
Mestizo
Other ethnic group
46 (21.3)
66 (30.6)
73 (33.8)
29 (13.4)
2 (0.9)
41 (20.9)
52 (26.5)
69 (35.2)
32 (16.3)
2 (1.0)
34 (20.9)
42 (25.8)
57 (35.0)
28 (17.2)
2 (1.2)
32 (20.9)
38 (24.8)
55 (35.9)
26 (17.0)
2 (1.4)
Mean age (± SD) (years) 25.4 (± 7.5) 27.0 (± 8.9) 25.7 (± 7.6) 27.6 (± 9.2)
Stratumb (percent)
Obstetric/postpartum infection
Vaginal delivery
Cesarean section
Gynecological/postoperative infection
181 (83.8)
79 (36.6)
85 (39.4)
34 (15.7)
169 (86.2)
66 (33.7)
87 (44.4)
27 (13.8)
136 (83.4)
60 (36.8)
60 (36.8)
27 (16.6)
132 (86.3)
50 (32.7)
68 (44.4)
21 (13.7)
Severe infection (percent) 60 (27.8) 48 (24.5) 42 (25.8) 35 (22.9)
Antimicrobial prophylaxis givenc (percent) 89 (41.2) 93 (47.4) 65 (39.9) 68 (44.4)
Diagnosis at entry (percent)
Endomyometritis
Septic abortion
Pelvic cellulitis
Pelvic abscess
Parametritis
Other
164 (75.9)
22 (10.2)
7 (3.2)
8 (3.7)
7 (3.2)
7 (3.2)
148 (75.5)
23 (11.7)
10 (5.1)
7 (3.6)
6 (3.1)
2 (1.0)
120 (73.6)
20 (12.3)
6 (3.7)
4 (2.5)
6 (3.7)
7 (4.3)
115 (75.2)
19 (12.4)
9 (5.9)
5 (3.3)
4 (2.6)
1 (0.7)
Median days on therapy (range) 4.0 (1–13) 4.0 (1–12) 4.0 (2–12) 4.0 (3–12)
aTreated patients for days on therapy. For ertapenem, n = 214; for piperacillin–tazobactam, n = 192;
bOne patient in the ertapenem group
was not included in the stratification counts because no primary diagnosis information was provided and the patient received no therapy;
cIncludes prophylaxis for surgical procedures and obstetric conditions; Pip–Taz, piperacillin–tazobactam; SD, standard deviation
Table 1 Baseline characteristics and therapy of randomized and clinically evaluable patients with acute pelvic
infection, by treatment groupin the supportive clinical MITT analysis, which
included 97.6% of the randomized patients (211
patients treated with ertapenem and 191 patients
treated with piperacillin–tazobactam), were
85.9% in the ertapenem group and 88.0% in the
piperacillin–tazobactam group. This reflects the
more conservative approach in the MITT out-
come assessment, in which patients with in-
adequate information or indeterminate outcomes
were considered to be cases of treatment failure.
The difference (95% CI) between the response
rates in the two clinical MITT groups of -2.1%
(-9.2% to 5.0%) indicates that the two treatment
groups were similar, which is consistent with the
results of the primary efficacy analysis. Among
patients with postpartum endomyometritis, cure
rateswerehigherinthosewhohadvaginaldelivery
(ertapenem, 95.0% or 57/60; piperacillin–
tazobactam, 96.0% or 48/50) than in those who
underwentCesarean section(ertapenem, 91.7% or
55/60;piperacillin–tazobactam,86.8%or59/68).
Table 2 shows the cure rates for clinically
evaluable patients in the two treatment groups by
stratum (at completion of study therapy and at
the TOC assessment), severity of infection and
primary diagnosis. More than 90% of the patients
in each stratum or subgroup of both treatment
groups had a favorable clinical response, with one
exception. In patients with severe infection, cure
rates were 95.2% for those in the ertapenem group
and 85.7% for thosein thepiperacillin–tazobactam
group. Statistical analyses within subgroups, such
aspatientswithsevere infection,werenotspecified
a priori and therefore were not performed. The
most common reason why patients were con-
sidered to have clinical failure at the TOC assess-
ment was persistent, unresolved or worsening
infection (7/10 or 70% of patients treated with
ertapenem and 7/13 or 53.8% of patients treated
withpiperacillin–tazobactam).Otherreasonswere
surgical intervention > 24 hours after study entry
(1/10 or 10% of patients in the ertapenem group
and 4/13 or 30.8% of those in the piperacillin–
tazobactam group), and surgical site infection
requiring additional antimicrobial therapy (2/10
or 20% of patients in the ertapenem group and
2/13 or 15.4% of patients in the piperacillin–
tazobactam group).
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Ertapenem Piperacillin–tazobactam
Stratum/subgroup n/m % response (95% CI) n/m % response (95% CI)
At DCIV
Stratum
Obstetric/postpartum infection
Gynecological/postoperative infection
130/137
25/26
94.9 (91.2, 98.6)
96.2 (88.6, 100)
122/132
19/21
92.4 (87.9, 97.0)
90.5 (77.6, 100)
Overall 155/163 95.1 (91.8, 98.4) 141/153 92.2 (87.9, 96.4)
At test of cure
Stratum
Obstetric/postpartum infection
Gynecological/postoperative infection
129/137
24/26
94.2 (90.2, 98.1)
92.3 (81.9, 100)
121/132
19/21
91.7 (86.9, 96.4)
90.5 (77.6, 100)
Severity
Moderate infection
Severe infection
113/121
40/42
93.4 (87.4, 97.1)
95.2 (83.8, 99.4)
110/118
30/35
93.2 (87.1, 97.0)
85.7 (69.7, 95.2)
Diagnosis
Endomyometritis
Septic abortion
111/120
20/20
92.5 (86.2, 96.5)
100 (83.2, 100)
104/115
19/19
90.4 (83.5, 95.1)
100 (82.4, 100)
Overall 153/163 93.9 (90.2, 97.6) 140/153 91.5 (87.1, 95.9)
n/m, ratio of number of patients cured/number of patients with assessment; CI, confidence interval; DCIV, discontinuation of IV therapy
Table 2 Cure rates in clinically evaluable patients, by stratum or subgroupThe time to resolution of baseline clinical
signs and symptoms was similar in each treatment
group. Patient signs and symptoms, assessed daily,
had resolved in 134 of 158 patients (84.8%) in the
ertapenem group and in 124 of 147 patients
(84.4%) in the piperacillin–tazobactam group at
completion of study therapy, and in 141 of 154
patients (91.6%) and 132 of 146 patients (90.4%),
respectively, at the TOC assessment. In addition,
theKaplan–Meiercurvesfortimetodefervescence
in the clinically evaluable patients who were
cured appeared to be similar for ertapenem and
piperacillin–tazobactam (data not shown). Defer-
vescence was prompt in each treatment group, as
90% of patients were afebrile, regardless of study
therapy, by study day 2.
The proportion of microbiologically evaluable
patients who at the TOC assessment had a favor-
able overall microbiological response (i.e. all base-
line pathogens were eradicated or presumed to be
eradicated) was 93.7% in the ertapenem group
and 93.8% in the piperacillin–tazobactam group.
Bacterial eradication/presumed eradication rates
at the TOC assessment, shown by the baseline
pathogenin Table3, weregenerally similar in both
treatment groups.Of thepatientswith an unfavor-
able microbiological response, persistence was
documented for only one pathogen (E. coli). For
all other pathogens, persistence was presumed
based on the clinical outcome.
Safety and local tolerability
In total, 214 patients in the ertapenem group and
192 patients in the piperacillin–tazobactam group
received at least one dose of study parenteral
therapy and were evaluated for adverse experi-
ences. During parenteral therapy and for 14 days
thereafter, one or more drug-related adverse
experiences were reported for 48 patients (22.4%)
in the ertapenem group and 43 patients (22.4%) in
the piperacillin–tazobactam group. The most
common drug-related adverse events were
mild gastrointestinal symptoms. Eight patients
(3.7%) who were treated with ertapenem and
four patients (2.1%) who were treated with
piperacillin–tazobactam had diarrhea. Vomiting
occurred in five patients (2.3%) in the ertapenem
group and four patients (2.1%) in the piperacillin–
tazobactam group, and six patients (2.8%) who
received ertapenem and three patients (1.6%)
who received piperacillin–tazobactam experi-
enced nausea. Five patients (2.3%) who received
ertapenem and five patients (2.6%) who received
piperacillin–tazobactam had headache.
One patient in the ertapenem group dis-
continued study therapy due to elevation of the
serum creatinine levels and renal insufficiency on
study day 3. The investigator considered this to be
a serious adverse event that was probably related
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Proportion (%) eradicated by:
Organism Ertapenem
Piperacillin–
tazobactam
Listeria monocytogenes
Other aerobic GPB
Staphylococcus aureus
Other staphylococci
Streptococcus agalactiae
Other streptococci
Enterococci
Other aerobic GPC
Escherichia coli
Other Enterobacteriaceae
Nonfermentative GNB
Other aerobic GNB
Neisseria spp.
Clostridium spp.
Other anaerobic GPB
Peptostreptococcus spp.
Other anaerobic GPC
Bacteroides fragilis group
Bacteroides fragilis
Other members of
B. fragilis group
Fusobacterium spp.
Porphyromonas spp.
Prevotella spp.
Other anaerobic GNB
Anaerobic GNC
1/1 (100)
4/5 (80.0)
9/9 (100)
17/17 (100)
11/11 (100)
25/27 (92.6)
23/23 (100)
3/3 (100)
37/41 (90.2)
20/22 (90.9)
3/4 (75.0)
NI
1/1 (100)
11/11 (100)
7/7 (100)
81/83 (97.6)
NI
30/30 (100)
15/15 (100)
15/15 (100)b
15/15 (100)
26/26 (100)
54/54 (100)
30/30 (100)
3/3 (100)
NI
2/2 (100)
16/16 (100)
15/16 (93.8)
16/16 (100)
18/21 (85.7)
30/31 (96.8)
NI
36/39 (92.3)
20/20 (100)
4/4 (100)
2/2 (100)
1/1 (100)
10/10 (100)
11/13 (84.6)
76/82 (92.7)
1/1 (100)
29/32 (90.6)
19/20 (95.0)
10/12 (83.3)c
9/11 (81.8)
22/23 (95.7)
46/50 (92.0)
14/14 (100)
2/2 (100)
NI, no isolates; GPB, Gram-positive bacilli; GPC, Gram-positive
cocci; GNB, Gram-negative bacilli; GNC, Gram-negative cocci.
aRepeat endometrial cultures were not collected from patients
who were cured;
bB. thetaiotaomicron (4/4), B. vulgatus (4/4),
B. distasonis (3/3), B. uniformis (2/2);
cB. thetaiotaomicron (5/6),
B. vulgatus (1/2), B. distasonis (4/4)
Table 3 Eradication/presumed eradication rates
a at
test of cure, by baseline pathogen isolated from the
site of the pelvic infection and/or from bloodto study therapy; concomitant medications
included ibuprofen. Antimicrobial therapy was
changed from ertapenem to ampicillin plus
clindamycin, both of which were discontinued on
study day 5 because the creatinine concentration
continued to rise. On study day 6, a nephrologist
was consulted. It was this consultant’s opinion that
the patient had acute interstitial nephritis or an
acute renal insult, most probably caused by
ibuprofen use. The serum creatinine concentra-
tionhad returned tonormalbystudyday10. Study
therapy was discontinued in three additional
patients in the ertapenem group, due to an over-
dose of study drug resulting from a pharmacy dis-
pensing error. No adverse effects associated with
the overdose were reported. None of the patients
in the piperacillin–tazobactam group had study
therapy discontinued because of a drug-related
adverse experience.
Drug-related laboratory adverse experiences
during parenteral therapy and for 14 days there-
after were reported in 26 patients (13.2%) in the
ertapenem group and 29 patients (15.7%) in
the piperacillin–tazobactam group. The most
common drug-related adverse laboratory events
were thrombocytosis(19/190 or 10.0% of patients
in the ertapenem group and 20/178 or 11.2% of
patients in the piperacillin–tazobactam group) and
elevation of liver enzymes as follows: alkaline
phosphatase, eight patients (4.6%) in the erta-
penem group and four patients (2.4%) in the
piperacillin–tazobactam group; alanine amino-
transferase, six patients (3.3%) and three patients
(1.8%), respectively; aspartate aminotransferase,
six patients (3.2%) and two patients (1.1%),
respectively.
In total, 26 patients (12.2%) in the ertapenem
group and 24 patients (12.5%) in the piperacillin–
tazobactam group experienced reactions of
moderate to severe intensity at the local infusion
site during parenteral therapy. The most common
symptom in both treatment groups was pain,
followed by tenderness and induration.
DISCUSSION
In this multicenter clinical trial, ertapenem
therapy, 1 g once a day, was highly effective for
treatment of women with acute pelvic infection,
including those with severe infection, and was
equivalent to treatment with piperacillin–
tazobactam given every 6 hours. In addition, the
time to defervescence and resolution ofothersigns
and symptoms was similar for both agents.
Approximately 94% of clinically evaluable patients
treated with ertapenem were cured, compared
with 92% of those who were treated with
piperacillin–tazobactam. These cure rates are
similar toorhigherthan thosereportedin previous
studies of patients with acute pelvic infection7–11,
and they are within the range of the expected cure
rate (i.e. approximately 90%) when evaluating a
new anti-infective drug for treatment of acute
pelvic infection12. As predicted, the success rates
in patients with septic abortion were excellent
(100%) in both treatment groups.
Ertapenem is highly active in vitro against
many Gram-positive and Gram-negative aerobic,
facultative andanaerobicbacteriathataregenerally
associated with infectionsacquired in the commu-
nity2,3. In this study, aerobic streptococci, Entero-
bacteriaceae, peptostreptococci and anaerobic
Gram-negative anaerobes, over 99% of which
were susceptible to ertapenem and piperacillin–
tazobactam, accounted for approximately 80%
of all isolates from microbiologically evaluable
patientsinbothtreatmentgroups.Otherinvestiga-
tors have also found that these same isolates are
responsible for most acute pelvic infections7–11.
In vitro, ertapenem has limited activity against
P. aeruginosa and enterococci. P. aeruginosa is rarely
recovered from patients with acute pelvic
infection. In this study, there were no isolates in
either treatment group. However, Enterococcus is
occasionally encountered in cultures from such
patients.Inthisstudy,23patientswhoweretreated
with ertapenem had a polymicrobial infection
that included Enterococcus, and all of them had a
favorable clinical and microbiological outcome at
the TOC assessment. This suggests that in poly-
microbial acute pelvic infections, additional
specific anti-enterococcal therapy is not required.
Similarly, many physicians consider enterococci
to be part of the normal vaginal flora rather
than pathogens, unless they are recovered in the
presence of a prosthesis13.
For acute pelvic infections, once-a-day dosing
with an antimicrobial agent such as ertapenem
Ertapenem for acute pelvic infection Roy et al.
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common treatment regimens that require
multiple daily doses and/or a combination of
antimicrobial agents. Suchadvantagesmay include
facilitation of outpatient therapy (either intra-
venously or by intramuscular injection), decreased
treatment costs14 and a potential reduction in
themedicationerrorrateinhospitalizedpatients15.
The overall safety profile and tolerability of
ertapenem in this study were similar to those
of piperacillin–tazobactam. Mild gastrointestinal
symptoms were the most frequently reported
drug-related clinical adverse events for both
agents.Themostcommondrug-relatedlaboratory
adverse events for both drugs were thrombo-
cytosis and mild to moderate elevation of liver
enzymes, both of which were transient and with-
out clinical consequence.
In summary, ertapenem 1 g once a day was
highly effective both clinically and micro-
biologically in the treatment of women with
moderate to severe acute pelvic infection. Erta-
penem therapy was as effective as therapy with
piperacillin–tazobactam, and had a comparable
overall safety and tolerability profile.
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